Glucagonlike peptide 1-based drugs and pancreatitis: Clarity at last, but what about pancreatic cancer?

JAMA Internal Medicine

Volumn 173, Issue 7, 2013, Pages 539-541

  Gier, Belinda ^a   Butler, Peter C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; SITAGLIPTIN;

ACUTE PANCREATITIS; BREAST CANCER; DIABETIC PATIENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; INSULIN BLOOD LEVEL; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS ADENOMA; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SOMATIC MUTATION;

DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HOSPITALIZATION; HUMANS; MALE; PANCREATITIS;

EID: 84876043035     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.3374     Document Type: Note

References (11)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14.
2. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretinbased therapies: review of the scientific evidence. J Clin Endocrinol Metab. 2011;96(7):2027-2031.
3. Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched casecontrol study [published online February 25, 2013]. JAMA Intern Med. 2013;173(7):534-539.
4. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med. 2008;358(18):1970-1972.
5. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-156.
6. Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat? Diabetes. 2012;61(5):986-988.
7. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008;1(4):306-316.
8. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model. Diabetes. 2012;61(5):1250-1262.
9. Gier B, Butler PC, Lai CK, Kirakossian D, De Nicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121-131.
10. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidylpeptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012;18(4):472-477.
11. Gale EA. Therapy: the second time as farce: rosiglitazone and the regulators. Nat Rev Endocrinol. 2011;7(1):5-6.